ホーム>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>ROC-325

ROC-325

カタログ番号GC32901

ROC-325 は、強力な抗がん作用を持つ強力な経口活性オートファジー阻害剤です。 ROC-325 は、リソソームの脱酸、オートファゴソームの蓄積、オートファジーの流れの乱れを誘発します。 ROC-325 は、腎細胞癌のアポトーシスも誘導します。

Products are for research use only. Not for human use. We do not sell to patients.

ROC-325 化学構造

Cas No.: 1859141-26-6

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$112.00
在庫あり
5mg
$101.00
在庫あり
10mg
$157.00
在庫あり
25mg
$313.00
在庫あり
50mg
$506.00
在庫あり
100mg
$911.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

ROC-325 is a novel inhibitor of autophagy.

ROC-325 is a novel inhibitor of autophagy. Treatment with ROC-325 results in a significant loss of acridine orange fluorescence. ROC-325 triggers a highly significant increase in cathepsin D (CTSD) levels. ROC-325 treatment yields pharmacodynamic effects that are consistent with inhibition of autophagy. Treatment with 5 μM ROC-325 for 24 hours leads to the formation of LC3B punctae and a robust increase in LC3B levels in both A498 and 786-0 RCC cells. Immunoblotting analysis conducted in both A498 and 786-0 cells demonstrates that ROC-325 promotes a dose-dependent increase in LC3B expression in a manner that correlated with a corresponding increase in the levels of p62 and cathepsin D[1].

ROC-325 treatment leads to significant, dose-dependent inhibition of disease progression. ROC-325 is well tolerated and no notable toxicities are observed other than a very modest, nonsignificant reduction in mean body weight at the highest dose. Immunohistochemical analysis of specimens collected from animals treated with ROC-325 demonstrates significant, dose-dependent increases in the autophagic markers LC3B and p62 and increases apoptosis[1].

[1]. Carew JS, et al. Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis. Clin Cancer Res. 2017 Jun 1;23(11):2869-2879.

レビュー

Review for ROC-325

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ROC-325

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.